Romidepsin: In the Treatment of T-Cell Lymphoma

ISSN： 0012-6667

Source： Drugs, Vol.71, Iss.11, 2011-07, pp. : 1469-1480

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The potential of pralatrexate as a treatment of peripheral T-cell lymphoma

By Dondi Alessandra Bari Alessia Pozzi Samantha Ferri Paola Sacchi Stefano

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 5, 2014-05 ,pp. : 711-718

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma

By Foss Francine M

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 9, 2011-09 ,pp. : 1141-1152

Informa Healthcare

Access to resources Recommend Favorite

Panobinostat is promising for the treatment of patients with cutaneous T-cell lymphoma

Inpharma, Vol. 1, Iss. 1653, 2008-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma

By Lansigan Frederick

Drugs, Vol. 70, Iss. 3, 2010-02 ,pp. : 273-286

Adis International

Access to resources Recommend Favorite

Beyond the Guidelines in the Treatment of Peripheral T-Cell Lymphoma: New Drug Development

By Chen Andy I. Advani Ranjana H.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 4, 2008-04 ,pp. : 428-435

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite